3-Hydroxyeticyclidine (3-HO-PCE) is a novel dissociative drug of the arylcyclohexylamine class, related to phencyclidine. It was first identified as a novel psychoactive substance in Sweden in 2017, and has subsequently been sold online as a research chemical. The toxicity and long-term safety profile of 3-HO-PCE is unknown as it has a very limited history of use, although one study indicates moderate potential toxicity.
Use and effects Early reports speculate that the dissociative effects may be described as "lying halfway between 3-MeO-PCP and 3-MeO-PCE."
Toxicity An in silico Study analyzing potential risks of 3-HO-PCE, along with other related substances, found multiple potential risks. One such risk was a high probability of hERG blockades, suggesting that QT-prolongation could be present in use. The lungs, liver, and blood were all found to be prominent likely toxicity targets of this class of drugs.
The LD50 of 3-HO-PCE and related substances in rats was consistently between 200-630mg/kg orally, indicating moderate oral toxicity.
Pharmacology
Pharmacodynamics 3-HO-PCE is known to block NMDA receptors, although little is known regarding its unique pharmacology.
Pharmacokinetics A study comprehensively reviewed the metabolism of 3-HO-PCE by using human liver microsomes and samples, both biological and non-biological, from a volunteer.
The first major metabolic pathway involves N-dealkylation, yielding the primary amine metabolite 3-HO-PCA. The second pathway causes the molecule to undergo oxidation, creating phenol-3-HO-PCE and hydroxy-3-HO-PCE. These compounds then undergo dehydration, creating dehydro-3-HO-PCE (which is also created directly from the parent compound via dehydrogenation). The third pathway causes the parent compound to undergo oxidative deamination, creating 1-(3'-hydroxyphenyl) cyclohexanol. This compound can either undergo oxidation and dehydrogenation to form dihydroxy-[1,1'-bi(cyclohexan)]-1-en-3-one, or a pathway involving dehydration and allylic oxidation to eventually form 3'4'-dihydro-[1,1'-biphenyl]-3-ol. The fourth pathway is phase II conjugation, where the parent compound undergoes O-glucuronidation to form 3-OGlu-PCE.
Chemistry 3-HO-PCE is composed of a central cyclohexane ring, substituted at the C1 position with an N-ethyl chain and a 3-hydroxyphenyl group. It is the 3-hydroxy analogue of PCE.
Society and culture Legal status
3-HO-PCE is illegal in Germany under the NpSG act, which serves as a blanket ban for various research chemicals.
It is also a controlled substance in the United Kingdom, Turkey, and Switzerland.
See also Arylcyclohexylamine 3-HO-PCP 3-MeO-PCE O-PCE
References
External links 3-HO-PCE - Isomer Design 3-HO-PCE - TrippyWiki